Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $184,264.08 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 6,136 shares of Akero Therapeutics stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $30.03, for a total transaction of $184,264.08. Following the completion of the sale, the insider now owns 74,158 shares in the company, valued at $2,226,964.74. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Catriona Yale also recently made the following trade(s):

• On Friday, September 20th, Catriona Yale sold 5,500 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.65, for a total transaction of $152,075.00.
• On Wednesday, September 18th, Catriona Yale sold 3,871 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.56, for a total transaction of $106,684.76.
• On Monday, September 16th, Catriona Yale sold 2,485 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.52, for a total value of $68,387.20.
• On Tuesday, September 10th, Catriona Yale sold 637 shares of Akero Therapeutics stock. The shares were sold at an average price of $26.18, for a total value of $16,676.66.
• On Friday, August 23rd, Catriona Yale sold 8,851 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.53, for a total value of $243,668.03.
• On Monday, August 26th, Catriona Yale sold 5,200 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.51, for a total transaction of $143,052.00.

Akero Therapeutics Stock Up 1.3 %

AKRO opened at $31.23 on Friday. The company has a current ratio of 24.89, a quick ratio of 24.89 and a debt-to-equity ratio of 0.04. The stock’s fifty day simple moving average is $27.36 and its 200 day simple moving average is $24.24. Akero Therapeutics, Inc. has a 1-year low of $11.25 and a 1-year high of $37.00. The stock has a market cap of $2.16 billion, a PE ratio of -9.76 and a beta of -0.25.

Akero Therapeutics (NASDAQ:AKRO) last posted its earnings results on Friday, August 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.09. As a group, research analysts expect that Akero Therapeutics, Inc. will post -3.64 earnings per share for the current year.

Institutional Investors Weigh In On Akero Therapeutics

Hedge funds have recently bought and sold shares of the stock. Russell Investments Group Ltd. increased its stake in shares of Akero Therapeutics by 2,366.0% during the first quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock worth $31,000 after purchasing an additional 1,183 shares during the period. Headlands Technologies LLC increased its position in Akero Therapeutics by 253.5% during the 1st quarter. Headlands Technologies LLC now owns 4,217 shares of the company’s stock worth $107,000 after buying an additional 3,024 shares during the period. Ameritas Investment Partners Inc. increased its position in Akero Therapeutics by 20.0% during the 1st quarter. Ameritas Investment Partners Inc. now owns 6,175 shares of the company’s stock worth $156,000 after buying an additional 1,030 shares during the period. Los Angeles Capital Management LLC acquired a new stake in shares of Akero Therapeutics during the first quarter worth $211,000. Finally, Quattro Financial Advisors LLC boosted its position in shares of Akero Therapeutics by 43,378.3% in the first quarter. Quattro Financial Advisors LLC now owns 10,000 shares of the company’s stock valued at $253,000 after acquiring an additional 9,977 shares during the period.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Akero Therapeutics in a research report on Tuesday, September 17th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.20.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.